O-007Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (20th June 2018)

Record Type:: Journal Article
Title:: O-007Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (20th June 2018)
Main Title:: O-007Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO
Authors:: Rossini, D
Cremolini, C
Conca, E
Del Re, M
Busico, A
Pietrantonio, F
Bergamo, F
Danesi, R
Cardellino, G
Tamburini, E
Dell'Aquila, E
Strippoli, A
Masi, G
Tonini, G
Negri, F
Corsi, D
Pella, N
Intini, R
Falcone, A
Santini, D
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 5
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 5
Issue Display:: Volume 29, Issue 5 (2018)
Year:: 2018
Volume:: 29
Issue:: 5
Issue Sort Value:: 2018-0029-0005-0000
Page Start:
Page End:
Publication Date:: 2018-06-20
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy149.006 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12263.xml